WELCOME TO The Biotechnology REPORT
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
CELL AND GENE THERAPY
LUMICKS | March 24, 2022
LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer.
The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...
Lummus Technology, LLC | February 14, 2022
Lummus Technology announced that its Green Circle business and Synthos S.A. have reached a major milestone in the development of advanced bio-butadiene technology. After completing a successful feasibility study in 2021, Lummus and Synthos have concluded that the bio-butadiene technology is ready for implementation, and the companies have agreed to move into the engineering and design phase of the project.
Given the confidence in the technology and the strong market demand for ren...
BioAgilytix | August 17, 2021
BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds ...
PR Newswire | April 07, 2020
Many companies searching for an effective therapy or vaccine for the present world health crisis are focusing on creating a vaccine from the immune system. Key to the race to develop a vaccine for the new coronavirus is a technology that uses the virus' genetic code to essentially persuade your body to make its own vaccine. This technique is faster than egg-based manufacturing, which produces the majority of annual flu vaccines… And it's enabling a possible vaccine for the new cor...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE